SEARCH

SEARCH BY CITATION

References

  • 1
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:725727.
  • 2
    The CONSENSUS Trial Study Group. Effect of Enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:14291435.
  • 3
    The IMPROVE Study Group. Acute and short-term hemodynam-ic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multi-center Prospective veterinary evaluation of enalapril study. J Vet Intern Med 1995;9:234242.
  • 4
    The COVE study group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243252.
  • 5
    Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998;213:15731577.
  • 6
    Kitagawa H, Wakamiya H, Kitoh K, et al. Efficacy of mono-therapy with benazepril, an angiotensin converting enzyme inhibitor, in dogs with naturally acquired chronic mitral insufficiency. J Vet Med Sci 1997;59:513520.
  • 7
    The BENCH (BENazepril in Canine Heart Disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:718.
  • 8
    Kolm U, Kosztolich A. Therapie des herzinsuffizienten hundes mittels benazepril-HCL (Fortekor): Ergebnisse einer langzeitstudie: Klinischer Verlauf und elektrokardiographische kontrolle. Wien Tier-ärztl Mschr 1999;86:289300.
  • 9
    Pedersen HD, Koch J, Poulsen K, et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Intern Med 1995;9:328333.
  • 10
    Brilla C, Maisch B. Regulation of the structural remodelling of the myocardium: From hypertrophy to heart failure. Eur Heart J 1994; 15:4552.
  • 11
    Cleland S, Reid J. The renin-angiotensin system and the heart: A historical review. Heart 1996;76:712.
  • 12
    Lee M, Bohm M, Paul M, et al. Tissue renin-angiotensin systems: Their role in cardiovascular disease Circulation 1993;87(Suppl 5):713.
  • 13
    Lindpaintner K, Wilhelm M, Jin T, et al. Tissue renin-angiotensin systems: Focus on the heart. J Hypertens 1987;5:3338.
  • 14
    Häggström J. Chronic Valvular Disease in Cavalier King Charles Spaniels—Epidemiology, Inheritance and Pathophysiology. Uppsala, Sweden: Swedish University of Agricultural Sciences; 1996. Thesis.
  • 15
    Tidholm A. Canine idiopathic dilated cardiomyopathy—Epidemiology, Histopathology and Pathophysiology. Uppsala: Swedish University of Agricultural Sciences, 2000. Thesis.
  • 16
    Kvart C, Häggström J, Pedersen HD. ACE inhibition in asymptomatic MR dogs: Results from a 4 year prospective, double blind, placebo controlled, monotherapy trial. Proceedings of the 18th Annual ACVIM Forum. 2000: 137138 (abstract).
  • 17
    Kvart C, Häggström J. ACE inhibition and mitral valve disease. Proceedings of the 17th Annual ACVIM Forum. 1999: 8384 (abstract).
  • 18
    Häggström J, Hansson K, Kvart C. Heart sounds and murmurs: Changes related to severity of mitral regurgitation in Cavalier King Charles Spaniels. J Vet Intern Med 1995;9:7583.
  • 19
    Suter PF, Lord PF. Thoracic Radiography, text atlas of thoracic diseases of the dog and cat. Wettswil , Switzerland : Selbstverlag PF Suter; 1984: 2443, 100–113, 480–497, 551–575.
  • 20
    Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:18871892.
  • 21
    Pedersen HD, Olsen LH, Mow T, Christensen NT. Neuroendo-crine changes in Dachshunds with mitral valve prolapse examined under different study conditions. Res Vet Sci 1999;66:1117.
  • 22
    Häggström J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angio-tensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:7782.
  • 23
    Tidholm A, Häggström J, Hansson K. Effects of dilated cardio-myopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. Am J Vet Res 2001;62:961967.
  • 24
    Koch J, Pedersen HD, Jensen AL, et al. Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy. Res Vet Sci 1995;59:172175.
  • 25
    Mow T, Pedersen HD. No expression of angiotensin II receptors and angiotensin-converting enzyme in myxomatous canine mitral valve leaflets. An autoradiographic study. J Vet Med Ser A 1999;46:465472.
  • 26
    Dell'italia L, Balcells E, Meng Q, et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol 1997;273:H961H970.
  • 27
    Häggström J, Hansson K, Karlberg B, et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996;57:16451652.
  • 28
    Kittleson M. Therapy of heart failure. In: EttingerSJ, FeldmanEC, ed. Textbook of Veterinary Internal Medicine, 5th ed. Philadelphia , PA : WB Saunders; 2000: 718.
  • 29
    Pedersen HD, Häggström J, Falk T, et al. Auscultation in mild mitral regurgitation in dogs: Observer variation, effects of physical maneuvers, and agreement with color Doppler echocardiography and phonocardiography. J Vet Intern Med 1999;13:5664.
  • 30
    Detweiler DK, Pattersson DF. The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 1965;127:481516.
  • 31
    Swenson L, Häggström J, Kvart J, et al. Relationship between parental cardiac status in Cavalier King Charles Spaniels and prevalence and severity of chronic valvular disease in offspring. J Am Vet Med Assoc 1996;208:20092012.
  • 32
    Olsen LH, Fredholm M, Pedersen HD. Epidemiology and inheritance of mitral valve prolapse in Dachshunds. J Vet Intern Med 1999;13:448456.
  • 33
    Klein J, Moeschberger M. Censoring and truncation. In: Survival Analysis. New York , NY : Springer-Verlag; 1997: 5579.
  • 34
    Hamlin R, Benitz A, Erickson G, et al. Effects of Enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. J Vet Intern Med 1997;10:8587.
  • 35
    Hamlin R, Nakayama T. Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. J Vet Intern Med 1998;12:9395.
  • 36
    Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994; 12:11771181.
  • 37
    Balcells E, Meng Q, Hageman G, et al. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol 1996;271:H417H421.
  • 38
    Ettinger SJ, Suter PF. Acquired valvular and endocardial heart disease. In: Canine Cardiology. Philadelphia , PA : WB Saunders; 1970: 324325.
  • 39
    Fischler M, Follath F. Comparative aspects of ACE-inhibitors: What differences are relevant. Schweiz Med Wochenschr 1999;129:10531060.